GW-0742

GW-0742 is a second-generation peroxisome proliferator-activated receptor delta (PPARd) agonist developed as a structural analog and pharmacological successor to GW-501516 (Cardarine). Like its predecessor, GW-0742 is not a SARM — it has no interaction with the androgen receptor and exerts no hormonal activity. It belongs to the same PPARd agonist class but was engineered with greater receptor selectivity and potency. Early comparative pharmacology data suggest GW-0742 binds PPARd with approximately 10-fold higher selectivity over PPARa and PPARg than GW-501516, potentially offering a cleaner metabolic activation profile.

GW-0742 activates PPARdelta in skeletal muscle, liver, and adipose tissue, upregulating the same gene networks as Cardarine — fatty acid beta-oxidation enzymes (CPT1B, ACOX1), mitochondrial biogenesis regulators (PGC-1a), and lipid transport proteins — but with enhanced receptor binding efficiency. Additionally, emerging research highlights GW-0742's anti-inflammatory properties: it has demonstrated potent suppression of NF-kB-mediated inflammatory signaling in vascular endothelial cells and macrophages, suggesting cardiovascular protective effects that extend beyond metabolic modulation.

The research literature on GW-0742, while less extensive than Cardarine's, consistently points to superior or equivalent fat oxidation, endurance enhancement, and lipid profile improvement. Researchers investigating next-generation PPARd agonism report enhanced exercise tolerance, reduced body fat percentage, improved triglyceride-to-HDL ratios, and anti-inflammatory benefits. GW-0742's higher PPARd selectivity may reduce off-target receptor activation, a theoretical advantage for long-duration research protocols.

GW-0742 is appropriate for researchers at any experience level, particularly those who have previously used Cardarine and seek an upgraded metabolic modulator with potentially improved selectivity. Its non-hormonal nature makes it universally stackable — it adds endurance and fat oxidation benefits to any SARM, peptide, or anabolic protocol without interaction concerns. Researchers focused on cardiovascular health optimization may prefer GW-0742 over GW-501516 due to its anti-inflammatory vascular properties.

GW-0742 has an elimination half-life estimated at 12–18 hours, supporting once-daily oral dosing. Oral bioavailability is high. There is zero testosterone suppression and no PCT requirement. No significant hepatotoxicity or adverse effects have been documented at standard research doses. As a newer and less extensively studied compound than Cardarine, GW-0742 has a smaller — though consistently positive — body of research. Typical protocols range from 10–20mg daily for 8–12 weeks. Researchers frequently run GW-0742 alongside SARMs during cutting phases, or as a standalone metabolic and cardiovascular optimization compound.